Amatuximab and novel agents targeting mesothelin for solid tumors

Paolo Baldo
Sara Cecco
Pharmacy Unit, Directorate Department, CRO Aviano-iRCCS National Cancer Institute, Aviano, Italy

Abstract: Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and cloned in 1996, MSLN seems to be involved in cell adhesion and metastasis. MSLN is prevalent in mesothelia tissues but is expressed in several human cancers, such as OC, pancreatic cancer, mesothelioma, and lung cancer. Amatuximab (MORAb-009) is a mouse-human chimeric monoclonal antibody with a selective affinity for MSLN. The principal mechanism of action comprises inhibition of binding of MSLN with the antigen CA125/MUC16. The highest phase of development is actually a Phase II trial (MORAb-009-201, Europe). In this review, we describe the mechanism of action of amatuximab and other MSLN-targeting novel drugs, along with a discussion about the expected efficacy, safety, and toxicity of this promising group of agents and implications for future research and clinical practice.

Keywords: amatuximab, monoclonal antibody, mesothelin, antigen, mesothelioma, target therapy

Plain language summary
Mesothelin (MSLN) is a glycoprotein, detectable on the surface of mesothelial cells. Although its biological function in normal cells is completely clarified, it is overexpressed in many types of cancer, and in cancerous cells, it may be involved in the promotion of cell proliferation, adhesion and migration, chemotherapy resistance, and inhibition of apoptosis. MSLN seems to be an interesting target in diagnosing and treating several solid tumors, in particular mesothelioma, which, for the aggressive nature of the disease, still represents one of the concrete challenges for modern oncology. In this review, we comprehensively describe MSLN as a potential target for cancer therapy, along with a presentation of profiles of the new agents under investigation for mesothelioma and other solid tumors. A list of ongoing clinical trials is provided.

Introduction
Mesothelin (MSLN) is considered an interesting and promising target for cancer research and therapy. It was initially identified as the cell surface antigen CAK1 by Chang et al in 1992; then, it was characterized and cloned as a 40-kDa glycoprotein detected on the surface of normal mesothelial cells. It is overexpressed by cancer cells in mesothelioma, ovarian cancer (OC), pancreatic cancer (PC), and other solid tumors. Relatively recent research detected high MSLN expression in acute myeloid leukemia and in cholangiocarcinoma. The name “mesothelin” was assigned to highlight the presence of the protein in normal mesothelial cells, including pleura, pericardium, fallopian tubes, trachea, and cornea.

The precursor, which is a 71-kDa protein that is encoded by a 2,138-bp-long cDNA and contains 628 amino acids, is then cleaved into two products, a ~31-kDa N-terminal...
region, called megakaryocyte potentiating factor (MPF), and the ~40-kDa mesothelin protein, which is the main
form represented on the cell surface. MSLN is commonly a membrane-bound, glycosylphosphatidylinositol (GPI)-linked
protein, but it is also detectable in a soluble form (soluble
MSLN protein [SMP]), which is shed from cancer cells. Patterns of MSLN expression in some types of cancer cells
are characterized by using immunohistochemistry, exploiting
the SAGE database, and using the antibody mAb5B2. Detection of MSLN in serum is a useful marker in cancer
diagnostic procedures.

The biological function of MSLN in normal cells is not completely clarified. It is likely to be involved in cell
adhesion, differentiation, and signal transduction, and in
in cancerous cells, it may be involved in the promotion of
proliferation, cell migration and spread, chemotherapy resistance,
and inhibition of apoptosis. The capability of MSLN
expression in some types of cancer cells is overexpressed
in solid tumors and in several B-cell malignancies, including acute lymphoblastic
lymphoma.

**MSLN as a therapeutic target in mesothelioma**

Mesothelioma is a rare cancer deriving from the mesothelium, which lines the pleura and other serous cavities (such as
the peritoneum, pericardium, and tunica vaginalis testis),
is the main form of cancer in these structures, and is often
categorized by a poor prognosis. Mesothelioma is described
in the benign or malignant subtypes. Surgery is the choice option
for the benign form, but in case of malignant transformation, the
overall estimated survival is 24–36 months. The malignant
form (malignant mesothelioma [MM]) has an epithelial
morphology, or a fibrous one, also called sarcomatoid, or
a combination of the two. MSLN is overexpressed in up to
95% of patients with the epithelioid form. In contrast, in the
sarcomatoid form (10%–15% of all mesotheliomas), there
is no overexpression of MSLN.

The crude annual incidence of MM in Europe is 2 new
cases per 100,000, while the prevalence is 3.5 cases per
100,000. According to data from the American Cancer Society, in the United States, the annual incidence is
estimated to be ~3,000 new cases per year. The global incidence trend indicates 36,925 incident cases in 2015
versus 26,376 in 2005, with an overall change of 40% due
to different factors (such as population growth, age trends,
and change in incidence).

The most important risk factor for the development of
MM is inhalation of asbestos, which induces oncogenesis via
the activation of the NF-κB-dependent pathway. Asbestos,
whose principal components are two types of fibers, serpen-
tine and amphibole, was largely used until 1980s–1990s, for
its excellent acoustic and thermal insulation properties and
its mechanical strength. A very long latency period – up to
25–40 years – can elapse before the development of this
tumor. Moreover, developed countries are gradually promot-
ing laws to restrict the use of asbestos, which means that
some countries expect that the peak incidence has already
been reached. Other known risk factors include therapeutic
radiation and genetic factors.

Diagnostic procedures include imaging, cytology, and
immunohistochemistry, but, to date, no technique is consid-
ered individually certain for the purposes of early diagnosis.
Surgery is applied with a prognostic/palliative intent, while
standard chemotherapy is based on a treatment with cisplatin
combined with an antifolate (pemetrexed or raltitrexed). New
therapeutic approaches under evaluation include angiogen-
esis inhibitors, mTOR inhibitors, and histone deacetylase
inhibitors. Given the overexpression of MSLN in >80% of
total MM cases, new agents targeting MSLN under evalua-
tion in clinical trials are considered a very promising field
for research and therapy.

**MSLN as a therapeutic target in other solid tumors**

MSLN seems to be overexpressed in ~30% of all cancers.
MSLN expression in different types of solid tumors is
described comprehensively by Hassan et al (see also The
Human Protein Atlas).

**Pancreatic cancer**

PC was investigated for the expression of MSLN by Argani
et al, Hassan et al, and Zervos et al, showing a high
expression of MSLN for most of the pancreatic adenocarcinomas but not in normal pancreatic cells. At the same time, their studies revealed the presence of MSLN in other adenocarcinomas of the biliary tract. Recent data confirm the hypothesis that new immunoagents actually investigated in clinical trials, such as LMB-100 (previously named RG7787), might have synergistic anticancer effects when used in combination with taxanes or other standard chemotherapy.39

**Ovarian cancer**

OC expresses, especially in the non-mucinous variant of cancer cells, high levels of MSLN. Hanaoka et al40 showed that 68.8% of OCs and 24.2% of borderline-type tumors express high MSLN levels, with implications for a shorter progression-free survival (PFS) and overall survival (OS). An analysis of MSLN expression is currently being performed by using immunohistochemistry and imaging techniques (immunoPET) with positron-emitting isotopes (68Zr-labeled mAbs and 64Cu-labeled mAbs) to evaluate the tumor uptake of innovative antibody-drug conjugate (ADC) immunotherapeutic agents.41,42 The resulting data will be helpful to predict the potential utility and efficacy of new immunoconjugates in the therapy of these types of cancer.43

**Breast cancer**

Currently, there is a plethora (451) of studies regarding targeted therapies for breast cancer (BC) (as reported in ClinicalTrials.gov trials register).44 However, only 5 studies correlated with MSLN as the main biomarker (for reference see Table 1). In treating BC, MSLN, as a target, may be particularly promising for triple-negative breast cancers (TNBC), one of the most aggressive forms of BC. Li et al investigated MSLN as a prognostic BC biomarker, whose expression is highly enriched especially in African–American women.45 These results are consistent with data published by Bayoglu et al46 and Parinyanitikul et al,47 who, respectively, reported a prevalence of 42.3% and 34% of patients expressing MSLN in TNBC. However, they suggested that MSLN overexpression may not have a prognostic value and does not correlate with the survival outcomes in patients with TNBC. Future work is needed to evaluate the potential of MSLN-targeted therapy in the treatment of BC.

**Lung cancer**

Ordonez, Miettinen and Sarlomo-Rikala performed immunohistochemistry studies using the MSLN-specific antibody 5B2 and showed that 38%–40% of lung adenocarcinomas stain positively for MSLN.48,49 In another study, the presence of the MSLN precursor was detected in 82% of lung adenocarcinoma, and its mature form was detected in 55% of patients.50

**Head and neck cancers**

The expression of MSLN in the human leptomeninges and meningiomas is not completely studied and understood. There are similarities in the structure and functions of the pleura and leptomeninges, and this suggests that MSLN might play a role in the meningeal function and could be expressed in meningiomas.51 Future research is necessary to better understand the possible role of MSLN as a target for therapy of gliomas, meningiomas, and/or other head and neck cancers. The overexpression of MSLN was also determined by immunohistochemistry in thymic carcinomas, suggesting that MSLN is a potential important target for this type of cancer.52,53

**Gastric cancer**

Tomoaki et al investigated the expression and extracellular secretion of MSLN in human gastric cancer cell lines and found lower expression levels in the human gastric cancer compared to those noted in human mesothelioma cells,54 and the levels were not specific to gastric cancer. Recently, Han et al55 found that 25.6% of a cohort of 117 patients with gastric carcinoma showed high levels of MSLN expression, which was associated with a poor prognosis. They concluded that MSLN-targeted therapies merit further research in patients with gastric carcinomas.

**MSLN targeting: amatuximab (MORAb-009)**

Amatuximab (alternative names: MORAb-009, anti-MSLN monoclonal antibody [MAb]) is a chimeric, humanized IgG1/k MAb that targets the cell surface MSLN. The precursor of MORAb-009 was isolated by Chowdhury et al in 199856 from a mouse splenic mRNA and was then optimized by fusing the gene encoding MSLN Fv (SS1 scFv) with human IgG1 and kappa regions.57 Amatuximab consists in 83% of human and 17% of murine sequences, and it is comprised of 2 identical heavy and 2 identical light chains connected by disulfide bonds. The substance can potentially reduce tumor growth by inhibiting MSLN binding to the extracellular substrate and also by antibody-dependent cellular cytotoxicity (ADCC). Amatuximab is not yet commercially available, and the highest development phase is Phase II. It is actually investigated in trials for the treatment of pleural mesothelioma and PC in the USA, Europe, Canada, and South America. Today, the primary focus is to evaluate its efficacy against mesotheliomas.
Pharmacology

Pharmacodynamics

After the characterization of amatuximab, Hassan et al\(^{57}\) performed preclinical studies to investigate the ability of amatuximab to target the MSLN protein expressed in some human cancer cells, to internalize in cancer cells after binding MSLN and to exert ADCC.

Results from the preclinical studies indicate a potential relevant interaction between amatuximab and tumorigenic cells/tissues overexpressing MSLN, and specifically:

- In immunohistochemistry studies, MSLN-positive tumor cells show strong cell surface staining, as reported by investigational medicinal product (IMP) dossier and by independent studies;\(^{58}\)
- In antibody-dependent cytotoxicity studies, amatuximab enhances ADCC in MSLN-positive cancer cell lines, but not at comparable levels in MSLN-negative cell lines;\(^{59,60}\)
- In standard in vivo murine xenograft studies, Hassan et al\(^{57}\) and Morphotek Inc. investigated the potential effects of amatuximab as a single agent or in combination with gemcitabine and rituximab. Amatuximab alone resulted in a significant reduction of tumor dimension in the intervention group (amatuximab-treated) compared to the control group (29.9% difference). Rituximab had no measurable effects, while some synergy with gemcitabine was detected, as an additive effect;
- In adhesion blocking assays, amatuximab inhibited the interaction of MSLN-expressing cells with MUC16-expressing cells, a factor considered of great importance for reducing cell adhesion, migration patterns, and finally metastasis.\(^{61}\)

Pharmacokinetics (PK)

Amatuximab, in actual clinical trials, is administered intravenously at the identified maximum tolerated dose (MTD) of 200 mg/m\(^2\). The main available data about MORAb-009 PK are described by Hassan et al,\(^{62}\) Gupta et al,\(^{63}\) and Fujisaka et al.\(^{64}\) The population PK analysis of the data collected from previous Phase I and Phase II studies in PC or malignant pleural mesothelioma (MPM) describes a two-compartment model, incorporating parallel linear and nonlinear (Michaelis–Menten) pathways for elimination from the central compartment. The nonlinear elimination is related to the interaction with the variable cell internalization of the antigen-antibody complex Ab-MSLN. In summary, PK studies estimate that a dose of 5 mg/kg, administered weekly, achieves a steady-state \(C_{\text{ss}}\) of 83.1 mg/mL and is considered a balanced reference dose for efficacy and safety in ~80% of subjects. The serum concentration–time profile of amatuximab suggests that after 5 weeks of weekly dosing, 89% of the steady-state concentration level is reached. Factors, including weight, age, gender, and race, seem not to influence the pharmacological effects of amatuximab. Combination schedules with other chemotherapy drugs, for example, cisplatin and pemetrexed therapies, show synergistic potentiation and reach a higher steady state \(C_{\text{ss}}\). Other models to investigate the distribution of amatuximab in the body and the patterns of penetration in cancer formations are based on imaging techniques using SPECT.\(^{65}\)

Safety and expected toxicity

Amatuximab is actually under investigation in several international trials. For this reason, the safety profile is implemented day after day following the adverse events (AEs) clinical reporting and applying pharmacovigilance signal detection. Phase I and Phase II studies investigated the safety and tolerability of amatuximab; although indicating a discrete tolerability, they showed that 54.2%\(^{62}\) to 76.5%\(^{64}\) of patients experienced AEs that were considered to be associated with the amatuximab treatment. Among a total of 41 patients in two studies (24+17, respectively), 10%–29.4% experienced AEs (including cytokine release syndrome, hot flushes, pyrexia, arthralgia, and nausea) that were potentially related to immune-mediated mechanism, which is relevant to the fact that amatuximab is a MAb. Other common AEs include fatigue (the most frequent), liver function elevation (AST, ALT, ALKP, and serum bilirubin), vomiting, decrease in appetite and weight, headache, hypotension, dizziness, and allergic reactions. It is reported that only one patient died of interstitial lung disease (ILD), and the cause was related to an AE to the amatuximab treatment.

Genotoxicity/teratogenity/pregnancy: available data

To date, no genotoxicity or teratogenicity or pregnancy studies have been planned and conducted for amatuximab. Amatuximab belongs to the pharmacological class of monoclonal antibodies and is expected not to be genotoxic.

Amatuximab in clinical studies

Amatuximab is investigated in trials for the treatment of pleural mesothelioma and PC in USA, Europe, Canada, and South America. The primary intention of researchers is the evaluation of its efficacy against mesotheliomas. An “investigational new drug application” was launched by Morphotek for amatuximab in 2006.
In this paper, we refer to amatuximab and other anti-MSLN agent studies citing the Clinical Trials Identifier (NCT number) in Medline (www.ClinicalTrials.gov). A summary of the clinical trials of amatuximab for MSLN-expressing tumors currently listed on ClinicalTrials.gov is presented in Table 2.

Initially, a Phase I clinical trial (NCT00325494) was planned, recruiting 24 subjects with PC or mesothelioma or non-small-cell lung cancer (NSLC) or OC. The primary outcome measures included the evaluation of safety and tolerability of amatuximab, the frequency and severity of the AEs and of the serious adverse events (SAEs), laboratory parameters, and cardiovascular examinations. The dose range that was investigated was between 12.5 and 400 mg/m². The MTD was set to 200 mg/m². A similar Phase I clinical trial (NCT01018784) was performed in 17 Japanese patients. The aims of the study were to determine dose-limiting toxicity (DLT) and MTD. In this trial, Fusisaka et al. reached similar conclusions, and the weekly dose was determined to be 200 mg/m². Taking into account an acceptable safety profile and the potential of obtaining clinical benefit, a subsequent Phase II, multicentric, single-arm, open-label trial (NCT00738582) recruited 89 patients presenting unresectable MPM. The primary objective was to improve PFS. The secondary outcome measures were the OS, overall response (OR), and evaluation of the safety profile of amatuximab. The PFS was not improved in the treatment group compared to the controls. However, the combined therapy of amatuximab plus pemetrexed/cisplatin gave encouraging results in terms of the median OS (14.8 months) and the objective response rate (ORR) (39%).

The study NCT00570713 was a Phase II, double-blind, randomized controlled trial, in which amatuximab was administered with gemcitabine in patients with unresectable PC. The patients were randomized to gemcitabine alone or gemcitabine plus amatuximab. The primary outcome was OS, and the secondary outcome measures were PFS and best ORR. The treatment arm (gemcitabine plus placebo) showed better results compared to amatuximab, for all the three main outcomes, but no statistical analysis was provided. The posted data are available at www.ClinicalTrials.gov.

NCT02357147 (acronym: ARTEMIS) was another Phase II clinical trial, started in 2015 with the main objective to evaluate the OS in patients with previously untreated, unresectable MPM. The standard chemotherapy regimen was administered to all the patients in combination with amatuximab or a placebo. After four or six induction cycles, the stable patients continued maintenance therapy with either amatuximab or placebo. The PFS, ORR, objective duration of response (DoR), and health-related quality of life (QoL) were the principal secondary outcome measures. In addition, the clinical development of the drug is ongoing. Two early Phase I mono-centric studies were conducted with the objective of investigating in vivo distribution and safety of 111In radio-labeled amatuximab in MSLN-expressing cancers (NCT01521325 and NCT01413451). Despite the small number of recruited patients (6 and 7, respectively), Lindenberg et al. reported their findings that 111In-amatuximab showed a good tolerability, the dosimetry profile was favorable, and the physiologic uptake was detectable in the liver, kidneys, spleen, and heart. The uptake of 111In-amatuximab was higher in mesotheliomas compared to PCs. This study was realized with the objective of refining imaging techniques in patients with advanced cancers.

**MSLN targeting: novel agents**

MSLN expression is rather limited in normal tissues, but it is highly elevated in some solid human tumors, such as malignant mesothelioma, PC, OC, and lung adenocarcinoma. This provides the rational basis to test different agents potentially targeting MSLN.

A summary of new agents undergoing clinical evaluation is presented in Table 1, including monoclonal antibodies, in the form of single agents or as ADCs, immunotoxins, vaccines, and chimeric T-cells, containing Fv fragments that recognize MSLN.

**SS1P**

SS1P is a recombinant anti-MSLN immunogenic toxin that is constructed by the fusion of a variable fragment of a murine anti-MSLN antibody with the pseudomonas exotoxin 38 (PE38) portion. SS1P was tested both as a single agent and in combination with chemotherapy. In one early Phase II clinical trial (NCT01362790), SS1P was administered in combination with pentostatin and cyclophosphamide with the aim of decreasing the immunogenicity of SS1P in patients with mesothelioma, lung cancer, or PC. The primary objectives of this study were to evaluate the tolerability and safety of a regimen of pentostatin and cyclophosphamide in combination with SS1 (dsFv)PE38 and to evaluate the ORR stratified by tumor type and the formation of antibodies SS1P. The rationale was that the administration of a conditioning regimen of pentostatin plus cyclophosphamide delays the
<table>
<thead>
<tr>
<th>Study ID (ClinTrial.gov)</th>
<th>Phase</th>
<th>Start date/ recruitment status</th>
<th>Sponsor or principal investigating research institute</th>
<th>Agent or pharmacological mechanism</th>
<th>Condition</th>
<th>Intervention</th>
<th>Main outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01445392*</td>
<td>I</td>
<td>November 13, 2007/ completed</td>
<td>NCI; CC</td>
<td>SS1 P</td>
<td>Mesothelioma</td>
<td>Multicycle or single cycle SS1P Pemetrexed Caspazin</td>
<td>Safety and MTD; Best ORR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pentostatin</td>
<td></td>
</tr>
<tr>
<td>NCT01362790*</td>
<td>I</td>
<td>May 11, 2011/active, not recruiting</td>
<td>NCI; CC</td>
<td>SS1 P</td>
<td>Mesothelioma</td>
<td>SS1(dsFv)PE38 Pentostatin Cyclophosphamide</td>
<td>ORR; SS1 antibody formation; Grade of ADEs; OS; PFS; DoR</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>Lung adenocarcinoma Pancreatic neoplasms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01051934*</td>
<td>I</td>
<td>December 29, 2009/ completed</td>
<td>NCI; CC</td>
<td>SS1 P</td>
<td>NSCLC Adenocarcinoma</td>
<td>SS1(dsFv)PE38 Paclitaxel Carboplatin Bevacizumab</td>
<td>Safe and tolerable doses; Pharmacokinetics; DoR; ORR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00066651*</td>
<td>I</td>
<td>July 2003/completed</td>
<td>NCI; (NCI)</td>
<td>SS1 P</td>
<td>NSCLC</td>
<td>SS1(dsFv)PE38 immunotoxin</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Solid tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT00006981*</td>
<td>I</td>
<td>December 2000/ completed</td>
<td>NCI; (NCI)</td>
<td>SS1 P</td>
<td>Mesothelioma</td>
<td>SS1(dsFv)PE38 immunotoxin</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Solid tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02810418*</td>
<td>I</td>
<td>June 10, 2016/ recruiting</td>
<td>NCI; CC</td>
<td>LBM-100</td>
<td>Neoplasms</td>
<td>LBM-100 Nab-paclitaxel</td>
<td>ORR, MTD, safety and tolerability of LBM-100+ Nab-paclitaxel</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td>Pancreatic neoplasms</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I</td>
<td>June 7, 2016/ recruiting</td>
<td>NCI; CC</td>
<td>LBM-100</td>
<td>Mesothelioma</td>
<td>LBM-100 Nab-paclitaxel</td>
<td>MTD; average time from treatment initiation to disease progression or death; proportion of patients at MTD at RECIST; listing and frequency of treatment-related ADEs</td>
</tr>
<tr>
<td>NCT03066302*</td>
<td>II</td>
<td>June 2017/not yet recruiting</td>
<td>Sidney Kimmel Comprehensive Cancer Center</td>
<td>CRS-207</td>
<td>Metastatic pancreatic adenocarcinoma</td>
<td>CRS-207 Epacadostat Pembrolizumab GVAX</td>
<td>6 months survival; recommended dose of Epacadostat; 6 months survival; OS; PFS; ORR; immune-related duration of response</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02575807*</td>
<td>I</td>
<td>January 2016/ recruiting</td>
<td>Aduro Biotech Inc.; Incyte Corporation</td>
<td>CRS-207</td>
<td>Platinum resistant: Ovarian cancer Fallopian cancer Peritoneal cancer</td>
<td>CRS-207 Epacadostat Pembrolizumab</td>
<td>Number of patients reporting hematologic and non-hematologic DLTs; Adverse events by CTCAE grades; ORR; PFS</td>
</tr>
<tr>
<td></td>
<td>II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02243371*</td>
<td>II</td>
<td>December 2014/active, not recruiting</td>
<td>Sidney Kimmel Comprehensive Cancer Center; Bristol MS; Aduro Biotech; American Association for Cancer Research</td>
<td>CRS-207</td>
<td></td>
<td>CRS-207 Nivolumab CY</td>
<td>OS; number of patients experiencing treatment-related ADEs; TTP; tumor marker kinetics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT</td>
<td>Ph</td>
<td>Dates</td>
<td>Sponsor/Partner(s)</td>
<td>Treatment/Pharmacology</td>
<td>Primary Tumor(s)</td>
<td>Other Measures</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----</td>
<td>---------------------</td>
<td>-----------------------------</td>
<td>------------------------</td>
<td>---------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>NCT02004262*</td>
<td>II</td>
<td>January 2014/ completed</td>
<td>Aduro Biotech Inc.</td>
<td>CRS-207</td>
<td>2nd line, 3rd line and greater metastatic pancreatic cancer</td>
<td>OS; treatment-related ADEs</td>
<td></td>
</tr>
<tr>
<td>NCT03102320*</td>
<td>I</td>
<td>May 26, 2017/ recruiting</td>
<td>Bayer</td>
<td>Anetumab-R</td>
<td>Neoplasms</td>
<td>MTD; ORR; ADEs; DoR; DRR; PFS</td>
<td></td>
</tr>
<tr>
<td>NCT03023722*</td>
<td>II</td>
<td>May 11, 2017/ recruiting</td>
<td>Howard Hochster; Bayer; Yale University</td>
<td>Anetumab-R</td>
<td>Pancreatic cancer</td>
<td>Response rate as measured per RECIST criteria; TTP; toxicity; OS; DoR; PFS</td>
<td></td>
</tr>
<tr>
<td>NCT02839681*</td>
<td>II</td>
<td>June 2017/ recruiting</td>
<td>NCI; CC</td>
<td>Anetumab-R</td>
<td>Lung neoplasms</td>
<td>MTD; incidence of serious and non-serious ADEs</td>
<td></td>
</tr>
<tr>
<td>NCT02824042*</td>
<td>I</td>
<td>September 7, 2016/ recruiting</td>
<td>Bayer</td>
<td>Anetumab-R</td>
<td>Medical oncology</td>
<td>Incidence of positive anti-drug antibody interaction; incidence of positive neutralizing antibody iter</td>
<td></td>
</tr>
<tr>
<td>NCT02751918*</td>
<td>I</td>
<td>June 8, 2016/ recruiting</td>
<td>Bayer</td>
<td>Anetumab-R</td>
<td>Ovarian neoplasms</td>
<td>Incidence of treatment-related ADEs, cycle 1 AUC; pharmacokinetics; immunogenicity as defined by the titer of anti-anetumab-R antibodies; incidence of neutralizing antibodies</td>
<td></td>
</tr>
<tr>
<td>NCT02696642*</td>
<td>I</td>
<td>August 14, 2016/ recruiting</td>
<td>Bayer</td>
<td>Anetumab-R</td>
<td>Neoplasms</td>
<td>Incidence of treatment-related ADEs, cycle 1 AUC; Pharmacokinetics; immunogenicity as defined by the titer of anti-anetumab-R antibodies; incidence of neutralizing antibodies</td>
<td></td>
</tr>
<tr>
<td>NCT02639091*</td>
<td>I</td>
<td>February 3, 2016/ recruiting</td>
<td>Bayer</td>
<td>Anetumab-R</td>
<td>Medical oncology</td>
<td>MTD; plasma concentration of anetumab-R; tumor response evaluation following mRECIST criteria; number of patients with a positive titer of anti-drug antibodies</td>
<td></td>
</tr>
<tr>
<td>NCT02610140*</td>
<td>II</td>
<td>December 3, 2015/ active, not recruiting</td>
<td>Bayer; ImmunoGen and MorphoSys</td>
<td>Anetumab-R</td>
<td>Mesothelioma</td>
<td>Number of patients with serious ADEs as a measure of safety and tolerability</td>
<td></td>
</tr>
<tr>
<td>NCT02485119*</td>
<td>I</td>
<td>August 14, 2015</td>
<td>Bayer</td>
<td>Anetumab-R</td>
<td>Neoplasms</td>
<td>Number of treatment-related AEs as a measure of safety and tolerability; Pharmacokinetic parameters for Bay 94-9343 (Cmax, AUC, tmax); tumor response based on RECIST; level of MSLN expression using immunohistochemistry</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Study ID (ClinTrial.gov)</th>
<th>Phase</th>
<th>Start date/ recruitment status</th>
<th>Sponsor or principal investigating research institute</th>
<th>Agent or pharmacological mechanism</th>
<th>Condition</th>
<th>Intervention</th>
<th>Main outcome measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01469793*</td>
<td>I</td>
<td>November 2011/ completed</td>
<td>Genentech, Inc.</td>
<td>DMOT4039A</td>
<td>Metastatic pancreatic adenocarcinoma Platinum-resistant ovarian cancer</td>
<td>DMOT4039A</td>
<td>MTD: Number of patients with DLTs; recommended Phase II dose</td>
</tr>
<tr>
<td>NCT02341625*</td>
<td>I</td>
<td>January 2015/active, not recruiting</td>
<td>Bristol-Myers Squibb</td>
<td>BMS-986148</td>
<td>Mesothelioma NSCLC Ovarian cancer Pancreatic cancer Gastric cancer</td>
<td>BMS-986148</td>
<td>Number and grade of AEs</td>
</tr>
<tr>
<td>NCT02884726*</td>
<td>I–II</td>
<td>August 2016/active, not recruiting</td>
<td>Bristol-Myers Squibb</td>
<td>BMS-986148</td>
<td>Advanced and/or metastatic solid tumors</td>
<td>BMS-986148</td>
<td>Incidence and grade of AEs and SAEs; MTDs</td>
</tr>
<tr>
<td>NCT03030001*</td>
<td>I–II</td>
<td>February 15, 2017/ recruiting</td>
<td>Ningbo Cancer Hospital</td>
<td>CAR-T-cells</td>
<td>Solid tumor Adult advanced cancer</td>
<td>PD-1 antibody expressing mesothelin-specific CAR-T-cells TAI-meso CAR-T-cells</td>
<td>Safety of infusion of autologous mesothelin-specific CAR-T-cells; response evaluation criteria of solid tumor; PFS; OS</td>
</tr>
<tr>
<td>NCT02706782*</td>
<td>I</td>
<td>March 2016/ recruiting</td>
<td>Shanghai GeneChem Co., Ltd.</td>
<td>CAR-T-cells</td>
<td>Pancreatic cancer</td>
<td>TAI-meso CAR-T-cells</td>
<td>Number of patients with ADEs; number of patients with tumor response; detection of transferred T-cells in the circulation using quantitative methods (PCR)</td>
</tr>
<tr>
<td>NCT01583686*</td>
<td>I</td>
<td>March 30, 2012/ recruiting</td>
<td>NCI; CC</td>
<td>CAR-T-cells</td>
<td>Cervical cancer Pancreatic cancer Ovarian cancer Mesothelioma Lung cancer</td>
<td>Anti-mesothelin CAR Fludarabine Cyclophosphamide Aldesleukin</td>
<td>Determine a safe dose and determine if this approach will result in an objective tumor regression; determine the in vivo survival of CAR gene-engineered cells</td>
</tr>
<tr>
<td>NCT number</td>
<td>I</td>
<td>Month/Year</td>
<td>Institution</td>
<td>CAR-T-cells</td>
<td>Disease(s)</td>
<td>Treatment</td>
<td>Objectives</td>
</tr>
<tr>
<td>-------------</td>
<td>-----</td>
<td>-----------------</td>
<td>--------------------------------------------------</td>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>NCT02580747*</td>
<td>I</td>
<td>October 2015/</td>
<td>Chinese PLA General Hospital</td>
<td>CAR-T-cells</td>
<td>Malignant mesothelioma, Pancreatic cancer, Ovarian tumor</td>
<td>Anti-meso-CAR vector transduced T-cells</td>
<td>Occurrence of study-related adverse events; anti-tumor responses to CAR-T-meso cells infusions</td>
</tr>
<tr>
<td>NCT01355965*</td>
<td>I</td>
<td>May 2011/active, not recruiting</td>
<td>University of Pennsylvania</td>
<td>CAR-T-cells</td>
<td>Malignant pleural mesothelioma</td>
<td>Autoologous T-cells</td>
<td>AEs; ORR</td>
</tr>
<tr>
<td>NCT02414269*</td>
<td>I</td>
<td>May 2015/recruiting</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>CAR-T-cells</td>
<td>Malignant pleural disease, Metastases, Breast cancer</td>
<td>iCasp9M28z T-cell infusions, Cyclophosphamide</td>
<td>Composite measure of severity and number of AEs; changes in serum levels of the biomarker soluble mesothelin-related peptide</td>
</tr>
<tr>
<td>NCT03054298*</td>
<td>I</td>
<td>March 1, 2017/ recruiting</td>
<td>University of Pennsylvania</td>
<td>CAR-T-cells</td>
<td>Lung adenocarcinoma, Ovarian cancer, Peritoneal carcinoma, Fallopian tube cancer, Mesotheliomas</td>
<td>Hu-CAR-T-meso cells</td>
<td>Number of participants with treatment-related AEs; clinical anti-tumor effect by RECIST criteria (modified for mesothelioma); PFS, OS</td>
</tr>
<tr>
<td>NCT02159716*</td>
<td>I</td>
<td>June 2014/completed</td>
<td>University of Pennsylvania</td>
<td>CAR-T-cells</td>
<td>Metastatic pancreatic adenocarcinoma, Epithelial ovarian cancer, Malignant epithelial pleural mesothelioma</td>
<td>CAR-T-meso</td>
<td>Number of AEs</td>
</tr>
</tbody>
</table>

Note: *All trial information is available at [https://ClinicalTrials.gov/ct2/show/[NCTidentifier]].

**Abbreviations:** AEs, adverse events; AEs, adverse events; AUC, area under the curve; CAR, chimeric antigen receptor; CC, National Institutes of Health Clinical Center; CTCAE, common terminology criteria for adverse events; CY, cyclophosphamide; DLT, dose-limiting toxicity; DoR, duration of response; DRR, durable response rate; MSLN, mesothelin.; MTD, maximum tolerated dose; NA, not available; NCi, National Cancer Institute; NSLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; SAEs, serious adverse drug events; TTP, time to progression.
<table>
<thead>
<tr>
<th>Study ID-NLM identifier (other acronyms)</th>
<th>Phase/number of patients enrolled</th>
<th>Start date/recruitment status</th>
<th>Sponsor or principal investigating research institute</th>
<th>Agent or pharmacological mechanism</th>
<th>Condition</th>
<th>Main outcome measures</th>
<th>Posted/published data (OS/PFS/other)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00325494 (MORB-009-001)</td>
<td>Phase I/24</td>
<td>May 2006/completed</td>
<td>Morphotek</td>
<td>MORAb-009</td>
<td>Pancreatic cancer, Mesothelioma, Ovarian cancer, NSCLC</td>
<td>Safety and tolerability as a measure of ADEs; safety and tolerability as a measure of clinical laboratory parameters; pharmacokinetics of MORAb-009; OTR; percentage of patients with antibodies against infliximab</td>
<td>NA</td>
</tr>
<tr>
<td>NCT01018784 (MORAb-009-J081-102)</td>
<td>Phase I/17</td>
<td>November 2009/completed</td>
<td>Eisai CO. Ltd; Eisai Inc.</td>
<td>MORAb-009</td>
<td>Cancer mesothelin-positive, Malignant pleural mesothelioma</td>
<td>DLT; complete response and partial response; best overall response rate in the RECIST evaluation</td>
<td>NA</td>
</tr>
<tr>
<td>NCT00738582 (Amatuximab/MORAb-009-003)</td>
<td>Phase II/89</td>
<td>December 2008/completed</td>
<td>Morphotek</td>
<td>MORAb-009, Pemetrexed, Cisplatin</td>
<td>Mesothelioma, malignant</td>
<td>OS, PFS; best overall response rate</td>
<td>PFS (months): 6.1 (in 51% treated pts) (95% CI: 5.8, 6.4) OS (months): 14.8 (95% CI: 12.4, 18.5)</td>
</tr>
<tr>
<td>NCT00570713 (MORAb-009-002)</td>
<td>Phase II/155</td>
<td>December 2008/completed</td>
<td>Morphotek</td>
<td>Placebo, Gemcitabine</td>
<td>Pancreatic cancer</td>
<td>OS, PFS; best overall response rate</td>
<td>PFS (months): 3.4 (95% CI: 1.9, 4.7) vs 3.5 (95% CI: 2.8, 4.9) OS (months): 6.5 (95% CI: 4.5, 8.1) vs 6.9 (95% CI: 5.4, 8.8)</td>
</tr>
<tr>
<td>NCT02357147 (ARTeMIS)</td>
<td>Phase II/108</td>
<td>November 2015/active, not recruiting</td>
<td>Morphotek</td>
<td>Placebo, MORAb-009, Pemetrexed, Cisplatin</td>
<td>Mesothelioma, ovarian cancer, NSCLC</td>
<td>OS, PFS, ORR, DoR; health-related QOL; evaluate ADEs and AEs</td>
<td>NA</td>
</tr>
<tr>
<td>NCT01521325 (MORAb-009-201)</td>
<td>Phase I/6</td>
<td>September 2011/completed</td>
<td>Morphotek</td>
<td>MORAb-009</td>
<td>Pancreatic cancer, Mesothelioma, Ovarian cancer, NSCLC</td>
<td>Determine biodistribution of radiolabeled amatuximab in tumor and non-tumor tissue; safety of a single IV of indium-CHX-A amatuximab; pharmacokinetics and serum level; uptake of indium-CHX-A amatuximab; correlate shed serum mesothelin to imaging biodistribution of radiolabeled amatuximab in tumor and non-tumor tissue; background ratio and maximum counts; CTCAE ADEs; pharmacokinetics; antibody uptake versus IHC mesothelin expression</td>
<td>NA</td>
</tr>
<tr>
<td>NCT01413451 (ARTeMIS)</td>
<td>Phase I/7</td>
<td>July 2011/terminated</td>
<td>National Cancer Institute; National Institute of Health Cancer Center</td>
<td>MORAb-009</td>
<td>Carcinoma, pancreatic ductal, Mesothelioma, Ovarian neoplasms, NSCLC</td>
<td>Biodistribution of radiolabeled amatuximab in tumor and non-tumor tissue; background ratio and maximum counts; CTCAE ADEs; pharmacokinetics; antibody uptake versus IHC mesothelin expression</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Abbreviations:** ADEs, adverse drug events; AEs, adverse events; CHX-A, (isothiocyanatobenzyl)-cyclohexyl-; CI, confidence interval; CTCAE, common terminology criteria for adverse events; DLT, dose-limiting toxicity; DoR, duration of response; IHC, immunohistochemistry; IV, intravenous; MORAb-009, amatuximab; NA, not available or not appropriate; NSCLC, non-small-cell lung cancer; ORR, objective response rate; OS, overall survival; OTR, objective tumor response; PFS, progression-free survival; QOL, quality of life; RECIST, Response Evaluation Criteria in Solid Tumors.
formation of anti-SS1P antibodies, allowing patients to receive multiple cycles of SS1P and, thus, potentiating the expected efficacy.

No data are actually available about a (completed) Phase I trial (NCT01051934) in which SS1P is administered in association with paclitaxel, carboplatin, and bevacizumab in lung adenocarcinoma.

**LMB-100**

LMB-100 (previously named RG7787) is a recombinant immunogenic toxin targeting MSLN. It is based on a humanized Fab fragment with a newly engineered PE24 and is conceived to reduce the induction of immunogenicity compared to SS1P. Two initial Phase I–II studies, started in June 2016, are recruiting patients with malignant mesothelioma (NCT02798536) and pretreated patients with pancreatic adenocarcinoma (NCT02810418). Recent data published by Zhang et al showed that LMB-100 enhanced its activity when it was used in combination with the taxane Nab-paclitaxel in treating mesothelioma.

**CRS-207**

CRS-207 is a live attenuated, recombinant Listeria monocytogenes designed to express MSLN and secrete it in the cytosol of the infected antigen-presenting cells. It shows a synergic activity in combination with GVAX pancreas, a cell vaccine expressing human granulocyte macrophage-colony-stimulating factor and a regimen of low dose cyclophosphamide, administered to potentiate antineoplastic activity and inhibit regulatory T-cells. In a Phase II clinical trial, cyclophosphamide/GVAX and CRS-207 prolonged survival in patients with PC with a favorable toxicity. The same combination was investigated in pretreated patients with metastatic adenocarcinoma of the pancreas compared to chemotherapy standard regimens or to CRS-207 as a single agent (NCT02004262). Two other Phase II studies are active. Although they are not yet recruiting patients, they intend to combine GVAX/CRS-207 with nivolumab (NCT02243371) or CRS-207 with epacadostat, an inhibitor of indolamine 2,3-dioxygenase (NCT03006302), and this study started in June 2017, with the aim of improving survival in the same setting. CRS-207 and epacadostat are also under investigation in OC (platinum-resistant), peritoneal tumor, and fallopian tumor (NCT02575807).

The combination of CRS-207 with cyclophosphamide and standard chemotherapy was tested in a Phase I study that was completed in June 2017, which enrolled 60 patients with MPM (NCT01675765). The main outcome measures are safety, the number of subjects reporting AEs, the induction of an immune response to MSLN by enzyme-linked immunosorbent spot assay, the objective tumor response and the time to progression. To date, no data have been posted about the results of this trial.

**BAY 94-9343**

BAY 94-9343, also called anetumab ravtansine is an antibody drug, conjugate to DM4, which is a tubulin polymerase inhibitor. Anetumab is designed to target MSLN on the cell surface and release the maytansinoid tubulin inhibitor into the cytoplasm after antibody internalization. In vitro, anetumab is markedly and selectively cytotoxic for MSLN overexpressing cells.

Several Phase I studies are still recruiting patients presenting different malignancies. An early Phase II study (NCT02610140), started in December 2015, investigated anetumab at a dose of 6.5 mg/kg, administered as a monotherapy to patients with pretreated MPM compared to vinorelbine as standard therapy. The primary objective is to test the superiority of anetumab ravtansine in PFS. The secondary outcome measures include the OS, DoR, ORR, patient-reported outcomes, and number of patients reporting ADEs as a measure of safety and tolerability. The study is active but is not actually recruiting patients.

Anetumab has reached Phase II of clinical development as a single agent in PC (NCT03023722) and lung cancer (NCT02839681), and these two studies just started to recruit patients (May and June 2017, respectively). Another trial is investigating anetumab in combination with pembrolizumab for MPM (NCT03126630).

**DMOT4039A**

DMOT4039A is an ADC consisting of the humanized IgG1 anti-MSLN mAb h7D9.v3 (αMSLN), combined with the antimitotic agent monomethyl auristatin E, by means of a protease-labile linker. After binding the ADC to the specific biological antigen, the complex MSLN-ADC is internalized, and the free form is released into the cytosol, which induces G2/M-phase growth arrest, cell death, and apoptosis. The specific antiproliferative activity in vitro and its potent antitumor activity in xenograft cancer models encourage researchers to test DMOT4039A in clinical trials. A multicenter, open-label, Phase I study is planned to assess the safety, tolerability, and PK of DMOT4039A in patients with unresectable PC or platinum-resistant OC (NCT01469793).

Cohorts of participants receive escalation...
doses of DMOT4039A. A total of 54 out of the 71 enrolled patients were treated every 21 days, and MTD was assessed at 2.4 mg/kg. Alternatively, in a weekly regimen, the dose was determined to be 1 mg/kg. Across both the schedules, the most common toxicities were gastrointestinal symptoms. In addition, grade 3 hyperglycemia and grade 3 hypophosphatemia, at 2.8 mg/kg, caused an interruption of dose escalation. A total of 6 patients (4 OC; 2 PC) had confirmed partial responses with DMOT4039A at 2.4–2.8 mg/kg every 21 days.95

BMS-986148
BMS-986148 is an anti-MSLN MAb-cytotoxic drug conjugate. No data are available about the detailed pharmacology of this agent, but it might be related to ADC MDX-1204, a MAb conjugated with the potent alkylating agent duocarmycin (MED2460).96 After cellular internalization, this agent prevents proliferation, leading to cell death and apoptosis. An initial first Phase I study planned to investigate the safety and tolerability of BMS-986148 in combination with nivolumab, with the principal aim of highlighting the most hazardous AEs and SAEs (NCT02341625).97 The secondary outcome measures consisted of the evaluation of PK parameters, immunogenicity, and a better understanding of pharmacodynamics. The anti-tumor activity was defined in terms of the ORR, DoR, PFS, and OS. This Phase I–II study should enroll a total of more than 400 patients with MM, NSCLC, OC, PC, and gastric cancer. A smaller parallel Phase I study (NCT02884726)98 started in October 2016 in a single center in Japan, with preliminary data planned by the end of 2017, is expected to provide important information about safety and tolerability of BMS-986148 in subjects with advanced and/or metastatic solid tumors.

CARs
CARs are cited by the journal Science as one of the “breakthroughs of 2013,”99 representing a promising concept of bio-immunotherapy. CARs are obtained by the combination of an antigen-recognition domain on the cell surface, derived from the single-chain variable fragment (scFv) and one (in first-generation CARs) or more (in third- to fourth-generation CARs) stimulatory domains inside the cell, which activate an immunologic response.100 The concept that led to CARs, together with adoptive T-cell processes, represents one of the main strategies applied to manipulate patient T-cells ex vivo, a process which involves removing the patient’s T-cells, genetically modifying them and infusing them back into the patient. However, because the CARs are capable of recognizing the target antigen via the scFv-binding domain, this results in T-cell activation in a major histocompatibility-independent manner.101 The possibility to adapt the binding moiety, while retaining the principal structure, confers CARs the opportunity to recognize any type of target and, therefore, to potentially affect any type of specific-antigen-expressing cancer. CARs demonstrate promising results against hematologic malignancies and show only minor results in the treatment of solid tumors. Few data on clinical trials are published to date. A summary of the ongoing trials involving CARs for solid tumors overexpressing MSLN was recently reported by Wang et al.102

A major concern with CARs is the potential dramatic risk of toxicity, predominantly labeled “on-target/off-tumor” toxicity and as a “cytokine stench phenomenon”;103 and probably, this is one of the reasons why clinical trials investigating CARs are proceeding at moderate speed.

Discussion and future perspectives
The only realistic weapon currently available in modern oncology is the identification of new biological targets and biomarkers, essentially specific to the single type of cancer, and an increasingly detailed understanding of their biological pathways.

Although, in recent decades, it has been possible to increase the OS or PFS in many patients, some types of cancer remain a concrete challenge for modern oncology. Important factors such as the difficulty of obtaining a precise diagnosis when the disease is still at an early stage, the aggressive nature of the disease, or a poor differentiation in the expression of biomarkers between healthy and malignant cells are critical key points that still make it difficult to manage some cancers. Mesothelioma certainly falls into this “difficult” cancer group and still requires more knowledge specifically aimed at understanding how the inflammatory processes, as in the case of asbestos, which has a very long latency period, are triggered.

Although the global use of asbestos, considered as – albeit not unique – the main cause of mesothelioma, is banned in most advanced countries since the 1980s and 1990s, the long latency prior to diagnosis of mesothelioma (up to 40 years)104 suggests that the incidence peak has not yet been reached in many countries. Furthermore, a very poor prognosis after diagnosis of mesothelioma (12–24 months) makes it really urgent to implement research on how to treat mesotheliomas. Treatment options depend on the age and status of the patients and on the stage at diagnosis. Surgery is not considered sufficient without adjuvant therapy, and
thus, several chemotherapy programs are applied, including cisplatin, the antimetabolites pemetrexed or raltitrexed, gemcitabine, vinorelbine and, optionally, a combination with antiangiogenic agents like bevacizumab.\textsuperscript{18,105}

MSLN, along with other biomarkers, is one of the targets that researchers are currently focusing on for diagnosing and treating mesotheliomas. Although the role of MSLN in cancer progression is not yet completely understood,\textsuperscript{106} many drugs targeting MSLN are currently under investigation in international, multicentric clinical trials. Hassan et al,\textsuperscript{34} Zhao et al,\textsuperscript{96} and, recently, Mancuso and Neal\textsuperscript{107} comprehensively reviewed the main strategies for targeting MSLN in mesothelioma and other solid tumors. By reading, in parallel, the data summarized by Hassan’s review\textsuperscript{34} and the results of Inaguma’s original immunohistochemistry research\textsuperscript{13} (using anti-MSLN antibodies 5B2 and MN-1), it is easy to appreciate how MSLN overexpression in many solid tumors makes this target a formidable potential ground for oncology research.

In the present paper, we describe the pharmacological profile of the promising anti-MSLN agent amatuximab, along with a summary of respective clinical trials (Table 2). Furthermore, we propose emerging data about prognostic factors in some solid tumors and updates about new agents targeting MSLN that are currently being investigated and provide an updated summary of the ongoing clinical trials (on Table 1), including those started in 2016 and 2017 (Table 1).

Amatuximab, an unconjugated antibody against MSLN, has an acceptable safety profile, but when it is used as a single agent, it shows only modest results in terms of stabilizing the disease.\textsuperscript{57,64} Nevertheless, a combination of amatuximab with chemotherapy shows clinical activity with no overlapping toxicities, in Phase II trials. These findings encourage researchers to perform additional studies with different chemotherapy combinations.

Immunotoxins are also considered a promising therapeutic strategy. However, to date, the main problem in using anti-MSLN recombinant immunotoxins is immunogenicity. A Phase I study shows that almost all of the enrolled patients develop anti-toxin antibodies after treatment with SS1P in combination with pemetrexed and cisplatin.\textsuperscript{69} Among the cohorts of patients treated with PE38-RIT, only one anaphylactic reaction was detected, after the first infusion of immunotoxin.\textsuperscript{108} Although immune-mediated reactions are very frequent, usually they are not serious. Skin rashes, even severity grade 3, are effectively treated with steroids.\textsuperscript{109} Many efforts have been made to reduce the immunological response to increase the effectiveness of the treatment, including a combination of an immune suppression therapy with pentostatin and cyclophosphamide, which demonstrated its clinical value. Several other strategies for reducing the immune response are under investigation, and they are included in actual research programs. Zhang et al\textsuperscript{79} recently showed that LMB-100, in combination with the taxane Nab-paclitaxel, in treating mesothelioma, has a synergistic activity, which could be useful in mitigating immunogenicity.

Antibodies against MSLN have a more efficient anti-tumor activity when they are conjugated with a cytotoxic molecule compared to the unconjugated drug, as demonstrated in preclinical and clinical studies.\textsuperscript{58} DM4, conjugated with anetumab, performs its cytotoxic activity mainly against rapidly replicating cells, reducing systemic toxicity, and, thus, widening its therapeutic window. Like other ADCs, it shows a favorable PK profile in terms of its half-life, increasing its therapeutic exposure with a less frequent dosing and limiting immunogenicity. On the other hand, the main toxicity associated with maytansinoid is the reduction of neutrophils, lymphocytes, reticulocytes, and platelets along with hepatotoxicity.\textsuperscript{110,111}

In conclusion, MSLN is shown to be a promising target for the treatment of several types of cancer. In treating BC, for example, MSLN may be particularly promising for the TNBC form, in which it is reported that up to 42.3% of patients show overexpression of MSLN.\textsuperscript{47} In lung adenocarcinoma, MSLN, in its mature form, is detected in 55% of patients,\textsuperscript{70} and in gastric carcinomas, the detection of elevated levels of MSLN is correlated with a poor prognosis.\textsuperscript{55}

Different therapeutic strategies are under investigation after obtaining promising preclinical results. The real goal will now be to enhance its efficacy, to identify patients who can achieve the best benefit, and to limit drug-related toxicities.

Recent Phase I and II clinical trials reinforced the hypothesis that MSLN is an important target for immunotherapy, and the objective is to confirm these preliminary data. At the same time, other studies should be designed to validate the utility of MSLN as a surrogate biomarker, thus making MSLN a predictor of the potential response to therapy. Serum MSLN laboratory assessment is a useful strategy for the future development of MSLN-targeted therapies, helping to select and recruit patients who can achieve the best expected benefits by this type of treatment. To date, soluble MSLN is the only tumor biomarker that has been approved by the US Food and Drug Administration for treating mesotheliomas.\textsuperscript{112} For the purpose of selecting patients with the highest chance of benefit from the treatment, another
research arm is focusing on PET and SPECT evaluation before ADC treatment. MSLN-specific tracers for SPECT and PET have been developed recently. Molecular imaging of tumor antibody uptake might have value in the upcoming drug development by identifying patients who may benefit from ADC treatment. Lambert et al performed an 89Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction with a Phase I study with the ADC DMOT4039A (NCT01832116). The aim of the study was to evaluate the antibody tumor uptake, the whole body distribution, and the relation between the uptake, response to treatment, and MSLN expression. The authors demonstrated that with (89)Zr-MMOT0530A-PET, PC and OC lesions were visualized, along with antibody distribution, and they concluded that this technique might potentially guide personalized antibody-based treatments.

Together with predictive and diagnostic innovative tools, it will be of paramount importance to identify effective ways to synergically combine therapeutic strategies. A combination of ADCs, recombinant immunotoxins (RITs), MABs with immunotherapeutic molecules, target therapies, or standard chemotherapy, when indicated, will provide pharmacological perspectives and will constitute the basis for pipelines at pharmaceutical companies.

For this reason, in addition to the current ongoing trials, new extensive randomized trials based on the combination treatments and on extended number of patients should be planned.

**Disclosure**

The authors report no conflict of interest in this work.

**References**


83. Sidney Kimmel Comprehensive Cancer Center; Bristol-Myers Squibb; Stand Up to Cancer; Aduro BioTech; American Association for Cancer Research. GVAX pancreas vaccine (with CY) and CRS-207 with or without nivolumab. Available from: https://clinicaltrials.gov/ct2/show/NCT02243371. NLM identifier: NCT02243371. Accessed June 10, 2017.


